AI Article Synopsis
- There hasn't been an effective treatment for advanced thyroid cancer until recently, but new targeted drugs are being developed to stop tumor growth and blood supply to tumors.
- In Japan, three promising drugs—sorafenib, vandetanib, and lenvatinib—are currently in phase 3 trials or have already been approved elsewhere.
- Once these drugs are available, it's important to distinguish between them to ensure they are administered effectively to patients.
Article Abstract
Up until now there have been no promising drugs for the treatment of advanced thyroid cancer, but the development of novel therapeutic agents is now anticipated as a result of the advent of molecular targeted drugs that inhibit tumor growth signals or angiogenesis. Against a background in which the development of numerous molecular targeted drugs for advanced thyroid cancer is being pursued worldwide, the development of sorafenib, vandetanib, and lenvatinib is currently also under way in Japan. All three of these compounds are undergoing phase 3 trials or have been approved abroad, and because they are in the final stage of development in Japan, they are expected to be introduced in clinical settings in the near future. After they have been introduced, it will be necessary to understand the differences between these compounds and to administer them to patients appropriately.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1507/endocrj.ej14-0107 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!